Long-Term Neuroprotective Effect and Safety of Antenatal Magnesium Sulfate on Preterm Infants

전가원 대한주산의학회 2023 Perinatology Vol.34 No.3

In 2010, the American College of Obstetricians and Gynecologists (ACOG) issued a Committee Opinion regarding the administration of antenatal magnesium sulfate (MgSO4) for fetal neuroprotection based on randomized controlled trials and meta-analyses. ACOG recommends the use of antenatal MgSO4 for fetal neuroprotection. Consequently, antenatal MgSO4 is administered to pregnant women with a gestational age of less than 32 weeks to provide fetal neuroprotection and reduce the risk of cerebral palsy and neurodevelopmental impairment. Since the use of antenatal MgSO4 for fetal neuroprotection, concerns about the safety of the fetus and newborn and doubts about the long-term neuroprotective effects of antenatal MgSO4 have been raised. There is still in controversies whether antenatal MgSO4 provides short-term and long-term neuroprotection, such as decreased substantial gross motor dysfunction, cerebral palsy and cognitive dysfunction. Furthermore, the fetal and neonatal adverse effects of antenatal MgSO4, such as decreased vascular tone, blood flow of the mesenteric artery, and intestinal motility are still controversial. Therefore, preclinical studies and rigorous multicenter large cohort studies are necessary to determine the neuroprotective effects and safety of antenatal MgSO4, as well as to determine the optimal dosage and duration of treatment. It is important to administer MgSO4 to pregnant women with caution, taking into consideration the potential impact on the fetus and newborn.

Bisphenol A leaching from polycarbonate baby bottles into baby food causes potential health issues

전가원 대한소아청소년과학회 2022 Clinical and Experimental Pediatrics (CEP) Vol.65 No.9

.

Clinical Application of Near-Infrared Spectroscopy in Neonates

전가원 대한신생아학회 2019 Neonatal medicine Vol.26 No.3

The incidence of cerebral palsy has not decreased despite advances in neonatal care. Preterm infants are at a high risk of cerebral palsy. Moreover, preterm infants might experience permanent neurological sequelae due to injury in the preterm brain. Although the etiology of preterm brain injury is not fully understood, preterm brain injury is strongly associated with abnormal cerebral perfusion and oxygenation. Monitoring systemic blood pressure or arterial oxygen saturation using pulse oximetry is not enough to guarantee proper cerebral perfusion or oxygenation. Early detection of improper cerebral perfusion can prevent irreversible cerebral damage. To decrease brain injury through the early detection of under-perfusion and deoxygenation, other diagnostic modalities are needed. Near-infrared spectroscopy can continuously and noninvasively monitor regional oxygen saturation (rSO2), which reflects the perfusion and oxygenation status of tissues at bedside. Near-infrared spectroscopy represents a balance between tissue oxygen supply and demand. Cerebral rSO2 monitoring has been used most frequently in neonatal cardiac surgery to monitor cerebral oxygenation and prevent hypoxic damage or shock. Recently, cerebral, renal, or splanchnic rSO2 in neonates is frequently monitored. The progression of a disease, brain injury, and death can be prevented by detecting changes in rSO2 values using near-infrared spectroscopy. In this article, the basic principles, usefulness, and applications of near-infrared spectroscopy in neonates are discussed.

Risk Factors of Transfusion in Anemia of Very Low Birth Weight Infants

전가원,신종범 연세대학교의과대학 2013 Yonsei medical journal Vol.54 No.2

Purpose: Anemia of prematurity is frequent in preterm infants, for which red blood cell (RBC) transfusion remains the treatment of choice. In this study, we attempted to evaluate the characteristics and risk factors of anemia of prematurity, and suggest ways to reduce anemia and the need for multiple transfusions. Materials and Methods: Preterm infants weighing less than 1500 g (May 2008-May 2009) were divided into two groups depending on whether they received RBC transfusions (transfusion group and non transfusion group). Hemoglobin (Hb) concentration, phlebotomy blood loss, and the amount of RBC transfusion were analyzed. Risk factors of anemia and RBC transfusions were analyzed. Results: Fifty infants that survived were enrolled in the present study: 39 in the transfusion group and 11 in the non transfusion group. Hb concentrations gradually decreased by eight weeks. In the transfusion group, gestational age and birth weight were smaller, bronchopulmonary dysplasia and sepsis were more frequent, full feeding was delayed, parenteral nutrition and days spent in the hospital were prolonged, and phlebotomy blood loss was greater than that in the non transfusion group. Conclusion: Anemia of prematurity was correlated with increased laboratory blood loss, decreased birth weight, prolonged parenteral nutrition, and delayed body weight gain. Accordingly, reducing laboratory phlebotomy loss and parenteral nutrition, as well as improving body weight gain, may be beneficial to infants with anemia of prematurity.

The First Korean Case of Cutaneous Lung Tissue Heterotopia

전가원,한성우,정지미,강미선,신종범 대한의학회 2010 Journal of Korean medical science Vol.25 No.9

Cutaneous lung tissue heterotopia is a very rare disorder where mature lung tissues develop in the skin. This is only the second known report of cutaneous lung tissue heterotopia, with the first by Singer et al. in 1998. A newborn infant had a hemangioma-like, freely movable mass connected to the anterior aspect of the sternal manubrium. Pathologic findings showed mature lung tissues with bronchi, bronchioles, and alveoli through the dermis and subcutis, and it was diagnosed as cutaneous lung tissue heterotopia. Cutaneous lung tissue heterotopia is hypervascular, so grossly it looks like a hemangioma. It can be differentiated from pulmonary sequestration, teratoma, bronchogenic cyst, and branchial cleft cyst by histology and the location of the mass. We describe the clinical, radiologic, and pathologic findings of a cutaneous lung tissue heterotopia, the first reported in Korea.

Identification of a De Novo Heterozygous Missense FLNB Mutation in Lethal Atelosteogenesis Type I by Exome Sequencing

전가원,이미나,정지미,홍승연,김영남,신종범,기창석 대한진단검사의학회 2014 Annals of Laboratory Medicine Vol.34 No.2

Background: Atelosteogenesis type I (AO-I) is a rare lethal skeletal dysplastic disorder characterized by severe short-limbed dwarfism and dislocated hips, knees, and elbows. AO-I is caused by mutations in the filamin B ( FLNB ) gene; however, several other genes can cause AO-like lethal skeletal dysplasias. Methods: In order to screen all possible genes associated with AO-like lethal skeletal dys- plasias simultaneously, we performed whole-exome sequencing in a female newborn hav- ing clinical features of AO-I. Results: Exome sequencing identified a novel missense variant (c.517G>A; p.Ala173Thr) in exon 2 of the FLNB gene in the patient. Sanger sequencing validated this variant, and genetic analysis of the patient’s parents suggested a de novo occurrence of the variant. Conclusions: This study shows that exome sequencing can be a useful tool for the identi- fication of causative mutations in lethal skeletal dysplasia patients.

Changes in the Incidence of Bronchopulmonary Dysplasia among Preterm Infants in a Single Center over 10 Years

전가원 대한신생아학회 2020 Neonatal medicine Vol.27 No.1

Purpose: Bronchopulmonary dysplasia (BPD) is one of the most fatal respiratory morbidities in preterm infants, causing adverse respiratory and neurodevelopmental outcomes. Despite advances in neonatal ventilator care, the incidence of BPD has been static or even increased. The purpose of this study was to evaluate the incidence of BPD in a single center over 10 years. Methods: Preterm infants with gestational age (GA) <30 weeks who were admitted to Inje University Busan Paik Hospital from January 2009 to December 2018 and survived 28 days or more were enrolled. The incidence of BPD according to year and GA and the risk factors of BPD were evaluated. Results: Among 629 infants, 521 infants who survived 28 days or more were enrolled (BPD group, n=252; non-BPD group, n=269). The incidence of BPD was 48.4%, with moderate to severe BPD accounting for 13.9%. In preterm infants with GA ≤25, 26 to 27, and 28 to 29 weeks, the incidences of BPD were 57.5%, 51.5%, and 14.6%, respectively, with moderate to severe BPD accounting for 23.8%, 10.5%, and 3.7%, respectively. The incidence of BPD decreased from 68% in 2009 to 34.3% in 2014. Subsequently, it increased. Surfactant re-dosing and patent ductus arteriosus were more frequent in the BPD group than in the non-BPD group. Conclusion: BPD did not decrease over the previous 10 years despite advances in neonatal care.

출생체중 1,000 g 미만의 초극소저출생체중아에서조기장관영양의 효과

전가원,박성은,최창원,황종희,장윤실,박원순 대한소아청소년과학회 2005 Clinical and Experimental Pediatrics (CEP) Vol.48 No.7

Purpose : With the recent improved survival of extremely low birth weight infants(ELBWI), enteral feeding has become a major issue. This study investigates the effects of early enteral feeding in ELBWI on their morbidity, duration of hospitalization, and mortality. Methods : ELBWI admitted to the neonatal intensive care unit at Samsung Medical Center from November 1994 to April 2004 who survived more than 14 days were enrolled. ELBWI were divided into two groups : an early feeding group(EF), in which enteral feeding was started within 3 days after birth; and a late feeding group(LF), in which enteral feeding was started beyond 3 days after birth. 80 ELBWI came under EF, and 131 ELBWI under LF. Results : Birth weight and gestational age did not differ between the two groups. In EF, the time to achieve full enteral feeding and the duration of parenteral nutrition were significantly shorter than in LF. The incidence of bronchopulmonary dysplasia was significantly lower in EF, but the incidences of sepsis, necrotizing enterocolitis, and cholestasis were not different between the two groups. There was no difference in the survival rate between the two groups, but the duration of hospitalization was significantly shorter in EF. Conclusion : Early enteral feeding in ELBWI did not increase the incidence of necrotizing enterocolitis and sepsis, but rather decreased the incidence of bronchopulmonary dysplasia and shortened the duration of hospitalization. 목 적 : 저자들은 출생체중 1,000 g 미만의 초극소저출생체중아에서의 생후 3일 이전에 시작한 조기장관영양의 효과와 부작용에 대해 알아보았다.방 법 : 1994년 11월부터 2004년 4월까지 본원 신생아 중환자실에 입원한 출생체중 1,000 g 미만의 초극소저출생체중아 총 266례 중 생후 14일까지 생존한 211례의 의무기록을 후향적으로 분석 조사하였다. 대상 환아를 조기장관영양(early feeding, EF)군(80례)과 후기장관영양(late feeding, LF)군(131례)으로 분류하여 두 군의 인구학적 및 주산기 인자, 장관영양과 관련된 인자 및 합병증, 사망률에 대해 알아보았다.결 과 : 인구학적 및 주산기 인자로 재태연령과 출생체중은 각각 EF군 27+1±2+1주, LF군 27+0±1+6주와 EF군 848±109 g, LF군 818±138 g으로 두 군간에 차이가 없었다. 임신성 고혈압과 호흡곤란증후군은 EF군에서 각각 14%, 69%, LF군에서 28%, 89%로 EF군에서 유의하게 적었으며 EF군에서 연구기간 중 후반기인 2000-2004년에 포함된 환아의 비율이 높았다. 성 비, 임신성 당뇨, 자궁 내 성장지연, 산전 스테로이드 투여, 융모양막염의 여부는 두 군간에 차이가 없었다. 장관영양과 관련된 인자로 EF군은 평균 생후 2일에 장관영양을 시작하였고 LF군은 9일에 장관영양을 시작하였다. 완전장관영양 도달시기는 EF군에서 평균 생후 33일, LF군에서 생후 47일로 EF군에서 유의하게 빨랐고 정맥영양 시행기간도 EF군에서 24일, LF군에서 33일로 EF군에서 유의하게 짧았다. 재원기간은 EF군에서 평균 생후 85일, LF군에서 103일로 EF군에서 유의하게 짧았다. 장관영양 불내성의 발생은 EF군에서 적었으나 통계적으로 유의한 차이는 없었다. 합병증과 관련된 인자로 기관지폐이형성증의 발생은 EF군에서 53%, LF군에서 71%로 EF군에서 유의하게 적었다. 괴사성 장염(EF군 1%, LF군 5%)과 패혈증(EF군 36%, LF군 46%)은 두 군간 유의한 차이가 없었으며 사망률, 뇌실내출혈, 뇌실주위백질연화증, 미숙아 망막증, 담즙정체증도 두 군간에 유의한 차이가 없었다.결 론:출생체중 1,000 g 미만의 초극소저출생체중아에서 생후 3일 이전에 시작한 조기장관영양은 괴사성 장염이나 패혈증과 같은 부작용의 증가 없이 완전장관영양 도달시간을 단축하였고 정맥영양 시행기간과 재원기간을 감소시켰으며 기관지폐이형성증의 빈도를 감소시키는 이로운 효과를 보임을 알 수 있었다.

Risk factors and screening timing for developmental dysplasia of the hip in preterm infants

전가원,Choo Hye Jung,Kwon Yong Uk 대한소아청소년과학회 2022 Clinical and Experimental Pediatrics (CEP) Vol.65 No.5

Background: The delayed diagnosis of developmental dysplasia of the hip (DDH) requires complex treatment and sometimes progresses to hip osteoarthritis. Purpose: This study aimed to evaluate the risk factors and screening time for DDH in preterm infants. Methods: A total of 155 preterm infants with a gestational age <32 weeks screened for DDH with ultrasonography were enrolled in this retrospective chart review. Results: The incidence of DDH was 6.45% (10 of 155). Gestational age, birth weight, sex ratio, and breech presentation did not differ significantly between infants treated for DDH (n=10) and nontreated infants (n=145) (gestational age, 29.2±1.4 weeks vs. 29.6±2.0 weeks, P=0.583; birth weight, 1,240±237 g vs. 1,295±335 g, P=0.607; female sex, 7 of 10 (70.0%) vs. 77 of 145 (53.1%), P=0.346; and breech presentation, 5 of 10 (50.0%) vs. 43 of 145 (29.7%), P=0.286, respectively). Performing the first ultrasonography earlier than 38 weeks of postmenstrual age (PMA) increased the risk of an abnormal finding by 3.76 times compared to performing it at ≥38 weeks of PMA. These abnormal findings on ultrasonography resolved spontaneously. Breech presentation increased the risk of minor abnormal findings on the first ultrasonography by 3.11 times versus nonbreech presentation and resolved spontaneously. DDH in preterm infants did not occur predominantly on the left side or in infants born with breech presentation. Conclusion: Performing ultrasonography screening earlier than 38 weeks of PMA caused unnecessary subsequent ultrasonography and overtreatment. Breech presentation was not a risk factor for DDH in preterm infants. However, breech presentation could increase the risk of minor abnormal findings at the 1st ultrasonography compared to nonbreech presentation, which resolved spontaneously. The etiology and risk factors for DDH in preterm infants are somewhat different from those for DDH in term infants.

A Comparison of AmBisome(R) to Amphotericin B for Treatment of Systemic Candidiasis in Very Low Birth Weight Infants

전가원,구수현,이장훈,황종희,김성신,이은경,장욱,장윤실,박원순 연세대학교의과대학 2007 Yonsei medical journal Vol.48 No.4

Purpose: Amphotericin B is considered the treatment of choice for systemic candidiasis, but adverse effects may limit its use. An alternative option for the treatment of candidiasis includes lipid preparations of amphotericin B. This study investigated the safety and efficacy of AmBisome(R), a lipid formulation of amphotericin B containing liposomal structures, for the treatment of systemic candidiasis in very low birth weight infants (VLBWI). Materials and Methods: Data from 26 VLBWI treated with AmBisome(R) in the study group (AmBisome group) from October 2003 to July 2006 were compared with data from 20 VLBWI treated with amphotericin B as a historical control (Amphotericin group). This study was a prospective, historical control, multi-center trial. Results: Candida spp. was isolated in 73% (19/26) of the cases for the AmBisome group and 90% (18/20) of the cases for the Amphotericin group. The fungal eradication rate and the time to eradication was 84% (16/19) and 9±8 days in the AmBisome group, and 89% (16/18) and 10±9 days in the Amphotericin group, respectively (p=0.680 vs p=0.712). The major adverse effects were lower in the AmBisome group (renal toxicity, 21% vs 55%, p=0.029; hepatotoxity, 25% vs 65%, p=0.014, AmBisome group vs Amphotericin group, respectively). There was no significant difference in mortality attributed to systemic candidiasis (12% in the AmBisome group, 10% in the Amphotericin group, p= 0.868). Conclusion: AmBisome(R) is effective and safe for treating systemic fungal infections in VLBWI. Amphotericin B is considered the treatment of choice for systemic candidiasis, but adverse effects may limit its use. An alternative option for the treatment of candidiasis includes lipid preparations of amphotericin B. This study investigated the safety and efficacy of AmBisome(R), a lipid formulation of amphotericin B containing liposomal structures, for the treatment of systemic candidiasis in very low birth weight infants (VLBWI). Materials and Methods: Data from 26 VLBWI treated with AmBisome(R) in the study group (AmBisome group) from October 2003 to July 2006 were compared with data from 20 VLBWI treated with amphotericin B as a historical control (Amphotericin group). This study was a prospective, historical control, multi-center trial. Results: Candida spp. was isolated in 73% (19/26) of the cases for the AmBisome group and 90% (18/20) of the cases for the Amphotericin group. The fungal eradication rate and the time to eradication was 84% (16/19) and 9±8 days in the AmBisome group, and 89% (16/18) and 10±9 days in the Amphotericin group, respectively (p=0.680 vs p=0.712). The major adverse effects were lower in the AmBisome group (renal toxicity, 21% vs 55%, p=0.029; hepatotoxity, 25% vs 65%, p=0.014, AmBisome group vs Amphotericin group, respectively). There was no significant difference in mortality attributed to systemic candidiasis (12% in the AmBisome group, 10% in the Amphotericin group, p= 0.868). Conclusion: AmBisome(R) is effective and safe for treating systemic fungal infections in VLBWI.